Em meio a uma epidemia que já ceifou vidas e multiplicou casos na maior metrópole do Brasil, o governador de São Paulo anunciou que o Instituto Butantan — uma das mais antigas e respeitadas instituições científicas do país — terá sua vacina contra a dengue pronta em setembro de 2024. Fruto de quatorze anos de pesquisa, a imunização de dose única promete proteger contra os quatro sorotipos da doença com cerca de 80% de eficácia, com produção prevista de 45 milhões de doses para uso público a partir de 2025. O anúncio chega num momento em que o Brasil depende de um fornecedor estrangeiro com est
Metrópoles
· Jan 31, 2024
· health
· 5 min read
High
Sourcing: Characterized
Butantan dengue vaccine on track for September launch, says São Paulo governor
January 2024 saw 7 deaths and over 10,000 dengue cases in São Paulo state, with infections in the capital quadrupling year-over-year.
◉
Health & Medicine
2746 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% match
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% match
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% match
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% match
Related Coverage
G1 · Aug 20
Pai agradece médicos após morte de gêmeas unidas pela cabeça: 'mais vitórias que derrotas'
Pai das gêmeas unidas pela cabeça que morreram em cirurgia de separação agradece empenho de mais de 50 profissionais do …
Folha de S.Paulo · Aug 20 Selton Mello se emociona ao receber Kikito de Cristal em GramadoSelton Mello recebeu o Kikito de Cristal no Festival de Gramado e se emocionou ao lembrar que era a primeira vez receben…
G1 · Aug 20 CEMEI Amiguinhos da Vila inaugura prédio moderno com capacidade para 320 alunosInaugurado novo prédio do CEMEI Amiguinhos da Vila em Montes Claros, com capacidade para 320 alunos, oito salas de aula,…
Folha de S.Paulo · Aug 20 Hepatites D e E circulam no Brasil e preocupam especialistasRevisão de 200 estudos com dados de 14,5 milhões de pessoas revela que hepatites D e E circulam no Brasil com prevalênci…
Bias & Framing
No detailed analysis data available for this lens. Try re-running lenses from the admin panel.
Geopolitical Impact
🌎
Brazil's Butantan Institute advances domestic dengue vaccine development, positioning Latin America as independent vaccine producer and reducing regional reliance on foreign pharmaceutical suppliers.
Escalation Risk
low
Confidence
MED
Brazil
Latin America
Global vaccine market
Brazil strengthens regional soft power and health sovereignty through domestic vaccine production. Reduces dependence on multinational pharmaceutical companies and establishes itself as a reliable vaccine developer for tropical diseases, enhancing influence in Global South health initiatives.
Similar to Brazil's successful development of yellow fever vaccine capabilities in the early 20th century, establishing regional health leadership and vaccine independence.
Economic Lens
📈
Brazil's Butantan Institute dengue vaccine expected September 2024, with 45M doses for public rollout in 2025, signaling major public health investment and potential pharma/healthcare sector growth.
Market Signal
bullish
Confidence
HIGH
Pharmaceuticals & Biotechnology
Healthcare & Public Health
Medical Devices & Diagnostics
Insurance (Health)
Labor (reduced dengue-related absences)
Households benefit from reduced dengue infection risk, lower healthcare costs from preventive vaccination, decreased productivity losses from illness, and improved quality of life. Single-dose convenience increases adoption likelihood.
Government likely to implement mass vaccination campaigns, potentially subsidizing or providing free doses through public health system. May influence healthcare budget allocation, establish vaccine distribution infrastructure, and set precedent for domestic vaccine development investment. Could reduce pressure on emergency healthcare services.